Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.

Pathangey LB, McCurry DB, Gendler SJ, Dominguez AL, Gorman JE, Pathangey G, Mihalik LA, Dang Y, Disis ML, Cohen PA.

Oncotarget. 2017 Feb 14;8(7):10785-10808. doi: 10.18632/oncotarget.13911.

2.

Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists.

Manrique SZ, Dominguez AL, Mirza N, Spencer CD, Bradley JM, Finke JH, Lee JJ, Pease LR, Gendler SJ, Cohen PA.

Oncotarget. 2016 Jul 12;7(28):42919-42942. doi: 10.18632/oncotarget.10190.

3.

Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges.

Hoelzinger DB, Dominguez AL, Cohen PA, Gendler SJ.

Cancer Res. 2014 Dec 1;74(23):6845-55. doi: 10.1158/0008-5472.CAN-14-0836. Epub 2014 Oct 8.

4.

Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.

Cohen PA, Ko JS, Storkus WJ, Spencer CD, Bradley JM, Gorman JE, McCurry DB, Zorro-Manrique S, Dominguez AL, Pathangey LB, Rayman PA, Rini BI, Gendler SJ, Finke JH.

Immunol Invest. 2012;41(6-7):680-710. doi: 10.3109/08820139.2012.703745. Review.

5.

Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses.

Smith SE, Hoelzinger DB, Dominguez AL, Van Snick J, Lustgarten J.

Cancer Immunol Immunother. 2011 Dec;60(12):1775-87. doi: 10.1007/s00262-011-1075-6. Epub 2011 Jul 26.

6.

Comparative kinetic analyses of gene profiles of naïve CD4+ and CD8+ T cells from young and old animals reveal novel age-related alterations.

Mirza N, Pollock K, Hoelzinger DB, Dominguez AL, Lustgarten J.

Aging Cell. 2011 Oct;10(5):853-67. doi: 10.1111/j.1474-9726.2011.00730.x. Epub 2011 Aug 7.

7.

Foxp3-positive macrophages display immunosuppressive properties and promote tumor growth.

Manrique SZ, Correa MA, Hoelzinger DB, Dominguez AL, Mirza N, Lin HH, Stein-Streilein J, Gordon S, Lustgarten J.

J Exp Med. 2011 Jul 4;208(7):1485-99. doi: 10.1084/jem.20100730. Epub 2011 Jun 13. Retraction in: J Exp Med. 2011 Nov 21;208(12):2561.

8.

Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses.

Hoelzinger DB, Smith SE, Mirza N, Dominguez AL, Manrique SZ, Lustgarten J.

J Immunol. 2010 Jun 15;184(12):6833-42. doi: 10.4049/jimmunol.0904084. Epub 2010 May 7.

9.

B7-H1 expression on old CD8+ T cells negatively regulates the activation of immune responses in aged animals.

Mirza N, Duque MA, Dominguez AL, Schrum AG, Dong H, Lustgarten J.

J Immunol. 2010 May 15;184(10):5466-5474. doi: 10.4049/jimmunol.0903561. Epub 2010 Apr 7.

10.

Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses.

Dominguez AL, Lustgarten J.

Vaccine. 2010 Feb 3;28(5):1383-90. doi: 10.1016/j.vaccine.2009.10.153. Epub 2009 Nov 18.

11.

Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice.

Sharma S, Dominguez AL, Manrique SZ, Cavallo F, Sakaguchi S, Lustgarten J.

Cancer Res. 2008 Sep 15;68(18):7530-40. doi: 10.1158/0008-5472.CAN-08-1635.

12.

Implications of aging and self-tolerance on the generation of immune and antitumor immune responses.

Dominguez AL, Lustgarten J.

Cancer Res. 2008 Jul 1;68(13):5423-31. doi: 10.1158/0008-5472.CAN-07-6436.

13.

CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged.

Sharma S, Dominguez AL, Hoelzinger DB, Lustgarten J.

Cancer Immunol Immunother. 2008 Apr;57(4):549-61. Epub 2007 Sep 8.

PMID:
17828396
14.

High accumulation of T regulatory cells prevents the activation of immune responses in aged animals.

Sharma S, Dominguez AL, Lustgarten J.

J Immunol. 2006 Dec 15;177(12):8348-55.

15.
16.

Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB.

Sharma S, Dominguez AL, Lustgarten J.

Exp Gerontol. 2006 Jan;41(1):78-84. Epub 2005 Nov 14.

PMID:
16289924
17.
18.

Aged mice develop protective antitumor immune responses with appropriate costimulation.

Lustgarten J, Dominguez AL, Thoman M.

J Immunol. 2004 Oct 1;173(7):4510-5.

19.

Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses.

Cuadros C, Lopez-Hernandez FJ, Dominguez AL, McClelland M, Lustgarten J.

Infect Immun. 2004 May;72(5):2810-6.

20.

The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity.

Lustgarten J, Dominguez AL, Cuadros C.

Eur J Immunol. 2004 Mar;34(3):752-761. doi: 10.1002/eji.200324427.

21.

Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection in tolerant Her-2/neu mice.

Cuadros C, Dominguez AL, Frost GI, Borgstrom P, Lustgarten J.

Cancer Res. 2003 Sep 15;63(18):5895-901.

22.

Evaluation of the treatment of severe forms of schistosomiasis mansoni with oxamniquine.

Coutinho A, Domínguez AL.

Rev Inst Med Trop Sao Paulo. 1980 Jan-Feb;22(1 Suppl 4):41-51, 157-67. English, Portuguese. No abstract available.

PMID:
7455509

Supplemental Content

Loading ...
Support Center